文献速递药物不良反应与药物警戒

患者报告在VigiBase信号检测中的价值:Lareb与乌普萨拉监测中心合作工作坊结果

Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
PubMed 文献 · Drug Saf · 2018-01-01

该研究从VigiBase中筛选患者报告占比>50%的药物-事件组合,应用vigiRank排序后由Lareb与乌普萨拉监测中心 staff 评估212个组合,其中20个(9%)产生8个信号。患者叙述提供了不良反应体验与影响细节,并显示患者会进行因果与个人风险评估。

要点

  • 患者报告可识别全球数据库中先前未知的不良反应及已知不良反应的新方面。
  • 212个评估组合中20个(9%)产生8个WHO国际药物监测规划内传播的信号。
  • 患者信息 leaflets 中不良反应描述对患者不充分,且与医护人员产品信息一致性差。

核心结论

  • 患者报告中描述的安全关切可在全球数据库中被识别,包括先前未知的不良反应及已知不良反应的新方面。
  • 患者报告提供对信号评估有价值的独特信息,应纳入信号检测。

研究设计与样本

  • 数据于2016年9月从VigiBase检索,药物-事件组合系列限制为患者报告>50%者,报告者类型按E2B标准定义为「消费者/非卫生专业人员」。
  • 应用vigiRank对患者报告排序以优先评估组合,由乌普萨拉监测中心与荷兰药物警戒中心Lareb staff 对组合分类,潜在信号进入深入临床审查。

主要发现

  • 评估的212个组合中,20个(9%)产生8个在WHO国际药物监测规划内传播的信号。
  • 患者信息 leaflets 审查显示对患者的不良反应描述不充分,并与医护人员产品信息存在一致性差的例子。
  • 患者叙述提供不良反应体验与影响的细节,以及患者进行因果与个人风险评估的证据。

关键数值与推荐

  • 药物-事件组合系列限制为患者报告>50%,报告者类型按E2B标准为「消费者/非卫生专业人员」。
  • 212个评估组合中20个(9%)产生8个信号。

临床怎么用

  • 在信号检测中纳入患者报告,可补充医护人员报告未覆盖的安全信息。
  • 关注患者信息 leaflets 与医护人员产品信息中不良反应描述的一致性与充分性。

局限性

  • 患者报告在信号检测中应用的方法学描述稀缺,已发表经验限于少数国家。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patient reporting in pharmacovigilance is important and contributes to signal detection. However, descriptions of methodologies for using patient reports in signal detection are scarce, and published experiences of how patient reports are used in pharmacovigilance are limited to a few individual countries. OBJECTIVE: Our objective was to explore the contribution of patient reports to global signal detection in VigiBase. METHODS: Data were retrieved from VigiBase in September 2016. Drug-event-combination series were restricted to those with >50% patient reports, defined as reporter type "Consumer/non-health professional" per E2B reporting standard. vigiRank was applied to patient reports to prioritize combinations for assessment. Product information for healthcare professionals (HCPs) as well as patient information leaflets (PILs) were used as reference for information on adverse drug reactions (ADRs). Staff from the Uppsala Monitoring Centre and the Netherlands Pharmacovigilance Centre Lareb categorized the combinations. Potential signals proceeded to a more in-depth clinical review to determine whether the safety concern should be communicated as a "signal." RESULTS: Of the 212 combinations assessed, 20 (9%) resulted in eight signals communicated within the World Health Organization (WHO) programme for international drug monitoring. Review of PILs revealed insufficient ADR descriptions for patients and examples of poor consistency with product information for HCPs. Patient narratives provided details regarding the experience and impact of ADRs and evidence that patients make causality and personal risk assessments. CONCLUSIONS: Safety concerns described in patient reports can be identified in a global database including previously unknown ADRs as well as new aspects of known ADRs. Patient reports provide unique information valuable in signal assessment and should be included in signal detection. Novel approaches to highlighting patient reports in statistical signal detection can further improve the contribution of patient reports to pharmacovigilance.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Watson S, Chandler RE, Taavola H, et al. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre. Drug Saf. 2018. PMID: 28933055. doi:10.1007/s40264-017-0594-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。